{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:21:34Z","timestamp":1792588894524,"version":"4.5.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004702","name":"Universit\u00e0 degli Studi di Genova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004702","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>The availability of disease-modifying therapies and newborn screening programs for spinal muscular atrophy (SMA) has generated an urgent need for reliable prognostic biomarkers to classify patients according to disease severity. We aim to identify cerebrospinal fluid (CSF) prognostic protein biomarkers in CSF samples of SMA patients collected at baseline (T0), and to describe proteomic profile changes and biological pathways influenced by nusinersen before the sixth nusinersen infusion (T302).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this multicenter retrospective longitudinal study, we employed an untargeted liquid chromatography mass spectrometry (LC-MS)-based proteomic approach on CSF samples collected from 61 SMA patients treated with nusinersen (SMA1 n=19, SMA2 n=19, SMA3 n=23) at T0 at T302. The Random Forest (RF) machine learning algorithm and pathway enrichment analysis were applied for analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The RF algorithm, applied to the protein expression profile of na\u00efve patients, revealed several proteins that could classify the different types of SMA according to their differential abundance at T0. Analysis of changes in proteomic profiles identified a total of 147 differentially expressed proteins after nusinersen treatment in SMA1, 135 in SMA2, and 289 in SMA3.<\/jats:p>\n                <jats:p>Overall, nusinersen-induced changes on proteomic profile were consistent with i) common effects observed in allSMA types (i.e. regulation of axonogenesis), and ii) disease severity-specific changes, namely regulation of glucose metabolism in SMA1, of coagulation processes in SMA2, and of complement cascade in SMA3.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This untargeted LC-MS proteomic profiling in the CSF of SMA patients revealed differences in protein expression in na\u00efve patients and showed nusinersen-related modulation in several biological processes after 10 months of treatment. Further confirmatory studies are needed to validate these results in larger number of patients and over abroader timeframe.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00018-024-05426-6","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T05:02:38Z","timestamp":1725944558000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Proteomics profiling and machine learning in nusinersen-treated patients with spinal muscular atrophy"],"prefix":"10.1007","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4571-611X","authenticated-orcid":false,"given":"Chiara","family":"Panicucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eray","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Bartolucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Casalini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Brolatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Pedemonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Baratto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Pintus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Principi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marika","family":"Pane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Sframeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Albamonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria A.","family":"Sansone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Bertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugur","family":"Sezerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Petretto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3426-2901","authenticated-orcid":false,"given":"Claudio","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,10]]},"reference":[{"key":"5426_CR1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","volume":"8","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Sumner CJ, Muntoni F, Darras BT, Finkel RS (2022) Spinal muscular atrophy. Nat Rev Dis Primers 8:52. https:\/\/doi.org\/10.1038\/s41572-022-00380-8","journal-title":"Nat Rev Dis Primers"},{"key":"5426_CR2","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1086\/338627","volume":"70","author":"M Feldk\u00f6tter","year":"2002","unstructured":"Feldk\u00f6tter M, Schwarzer V, Wirth R, Wienker TF, Wirth B (2002) Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet 70:358\u2013368. https:\/\/doi.org\/10.1086\/338627","journal-title":"Am J Hum Genet"},{"key":"5426_CR3","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","volume":"28","author":"M Calucho","year":"2018","unstructured":"Calucho M, Bernal S, Al\u00edas L, March F, Vencesl\u00e1 A, Rodr\u00edguez-\u00c1lvarez FJ, Aller E, Fern\u00e1ndez RM, Borrego S, Mill\u00e1n JM, Hern\u00e1ndez-Chico C, Cusc\u00f3 I, Fuentes-Prior P, Tizzano EF (2018) Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul Disord 28:208\u2013215. https:\/\/doi.org\/10.1016\/j.nmd.2018.01.003","journal-title":"Neuromuscul Disord"},{"key":"5426_CR4","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1093\/hmg\/8.7.1177","volume":"8","author":"UR Monani","year":"1999","unstructured":"Monani UR, Lorson CL, Parsons DW, Prior TW, Androphy EJ, Burghes AH, McPherson JD (1999) A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet 8:1177\u20131183. https:\/\/doi.org\/10.1093\/hmg\/8.7.1177","journal-title":"Hum Mol Genet"},{"key":"5426_CR5","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2016","unstructured":"Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC, Yamashita M, Rigo F, Hung G, Schneider E, Norris DA, Xia S, Bennett CF, Bishop KM (2016) Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 388:3017\u20133026. https:\/\/doi.org\/10.1016\/S0140-6736(16)31408-8","journal-title":"Lancet"},{"key":"5426_CR6","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1111\/ene.15499","volume":"30","author":"E Mercuri","year":"2023","unstructured":"Mercuri E, Baranello G, Boespflug-Tanguy O, De Waele L, Goemans N, Kirschner J, Masson R, Mazzone ES, Pechmann A, Pera MC, Vuillerot C, Bader-Weder S, Gerber M, Gorni K, Hoffart J, Kletzl H, Martin C, McIver T, Scalco RS, Yeung WY, Servais L, SUNFISH Working Group (2023) Risdiplam in types 2 and 3 spinal muscular atrophy: a randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment. Eur J Neurol 30:1945\u20131956. https:\/\/doi.org\/10.1111\/ene.15499","journal-title":"Eur J Neurol"},{"key":"5426_CR7","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","volume":"20","author":"E Mercuri","year":"2021","unstructured":"Mercuri E, Muntoni F, Baranello G, Masson R, Boespflug-Tanguy O, Bruno C, Corti S, Daron A, Deconinck N, Servais L, Straub V, Ouyang H, Chand D, Tauscher-Wisniewski S, Mendonca N, Lavrov A, STR1VE-EU study group (2021) Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol 20:832\u2013841. https:\/\/doi.org\/10.1016\/S1474-4422(21)00251-9","journal-title":"Lancet Neurol"},{"key":"5426_CR8","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","volume":"29","author":"DC De Vivo","year":"2019","unstructured":"De Vivo DC, Bertini E, Swoboda KJ, Hwu WL, Crawford TO, Finkel RS, Kirschner J, Kuntz NL, Parsons JA, Ryan MM, Butterfield RJ, Topaloglu H, Ben-Omran T, Sansone VA, Jong YJ, Shu F, Staropoli JF, Kerr D, Sandrock AW, Stebbins C, Petrillo M, Braley G, Johnson K, Foster R, Gheuens S, Bhan I, Reyna SP, Fradette S, Farwell W, NURTURE Study Group (2019) Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study. Neuromuscul Disord 29:842\u2013856. https:\/\/doi.org\/10.1016\/j.nmd.2019.09.007","journal-title":"Neuromuscul Disord"},{"key":"5426_CR9","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss KA, Farrar MA, Muntoni F, Saito K, Mendell JR, Servais L, McMillan HJ, Finkel RS, Swoboda KJ, Kwon JM, Zaidman CM, Chiriboga CA, Iannaccone ST, Krueger JM, Parsons JA, Shieh PB, Kavanagh S, Wigderson M, Tauscher-Wisniewski S, McGill BE, Macek TA (2022) Onasemnogene Abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the phase III SPR1NT trial. Nat Med 28:1390\u20131397. https:\/\/doi.org\/10.1038\/s41591-022-01867-3","journal-title":"Nat Med"},{"key":"5426_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3233\/JND-210735","volume":"9","author":"KA Rich","year":"2022","unstructured":"Rich KA, Fox A, Yalvac M, Heintzman S, Tellez M, Bartlett A, Severyn S, Linsenmayer M, Kelly K, Reynolds J, Sterling GB, Weaver T, Rajneesh K, Pino MG, Arnold WD, Elsheikh B, Kolb SJ (2022) Neurofilament levels in CSF and serum in an adult SMA cohort treated with Nusinersen. J Neuromuscul Dis 9:111\u2013119. https:\/\/doi.org\/10.3233\/JND-210735","journal-title":"J Neuromuscul Dis"},{"key":"5426_CR11","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/jnc.14953","volume":"153","author":"T Kessler","year":"2020","unstructured":"Kessler T, Latzer P, Schmid D, Warnken U, Saffari A, Ziegler A, Kollmer J, M\u00f6hlenbruch M, Ulfert C, Herweh C, Wildemann B, Wick W, Weiler M (2020) Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy. J Neurochem 153:650\u2013661. https:\/\/doi.org\/10.1111\/jnc.14953","journal-title":"J Neurochem"},{"key":"5426_CR12","doi-asserted-by":"publisher","first-page":"4329","DOI":"10.3390\/ijms22094329","volume":"22","author":"L Bianchi","year":"2021","unstructured":"Bianchi L, Sframeli M, Vantaggiato L, Vita GL, Ciranni A, Polito F, Oteri R, Gitto E, Di Giuseppe F, Angelucci S, Versaci A, Messina S, Vita G, Bini L, Aguennouz M (2021) Nusinersen Modulates Proteomics Profiles of Cerebrospinal Fluid in spinal muscular atrophy type 1 patients. Int J Mol Sci 22:4329. https:\/\/doi.org\/10.3390\/ijms22094329","journal-title":"Int J Mol Sci"},{"key":"5426_CR13","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.3390\/biom12101431","volume":"12","author":"F Errico","year":"2022","unstructured":"Errico F, Marino C, Grimaldi M, Nuzzo T, Bassareo V, Valsecchi V, Panicucci C, Di Schiavi E, Mazza T, Bruno C, D\u2019Amico A, Carta M, D\u2019Ursi AM, Bertini E, Pellizzoni L, Usiello A (2022) Nusinersen induces Disease-Severity-Specific Neurometabolic effects in spinal muscular atrophy. Biomolecules 12:1431. https:\/\/doi.org\/10.3390\/biom12101431","journal-title":"Biomolecules"},{"key":"5426_CR14","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1111\/ene.15331","volume":"29","author":"DC Schorling","year":"2022","unstructured":"Schorling DC, K\u00f6lbel H, Hentschel A, Pechmann A, Meyer N, Wirth B, Rombo R, SMArtCARE consortium, Sickmann A, Kirschner J, Schara-Schmidt U, Lochm\u00fcller H, Roos A (2022) Cathepsin D as biomarker in cerebrospinal fluid of nusinersen-treated patients with spinal muscular atrophy. Eur J Neurol 29:2084\u20132096. https:\/\/doi.org\/10.1111\/ene.15331","journal-title":"Eur J Neurol"},{"key":"5426_CR15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00018-023-04885-7","volume":"80","author":"I Faravelli","year":"2023","unstructured":"Faravelli I, Gagliardi D, Abati E, Meneri M, Ongaro J, Magri F, Parente V, Petrozzi L, Ricci G, Far\u00e8 F, Garrone G, Fontana M, Caruso D, Siciliano G, Comi GP, Govoni A, Corti S, Ottoboni L (2023) Multi-omics profiling of CSF from spinal muscular atrophy type 3 patients after nusinersen treatment: a 2-year follow-up multicenter retrospective study. Cell Mol Life Sci 80:241. https:\/\/doi.org\/10.1007\/s00018-023-04885-7","journal-title":"Cell Mol Life Sci"},{"key":"5426_CR16","doi-asserted-by":"publisher","first-page":"6696","DOI":"10.3390\/jcm12206696","volume":"12","author":"M Beaudin","year":"2023","unstructured":"Beaudin M, Kamali T, Tang W, Hagerman KA, Dunaway Young S, Ghiglieri L, Parker DM, Lehallier B, Tesi-Rocha C, Sampson JB, Duong T, Day JW (2023) Cerebrospinal fluid proteomic changes after Nusinersen in patients with spinal muscular atrophy. J Clin Med 12:6696. https:\/\/doi.org\/10.3390\/jcm12206696","journal-title":"J Clin Med"},{"key":"5426_CR17","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.3390\/jcm12155060","volume":"12","author":"M Babi\u0107","year":"2023","unstructured":"Babi\u0107 M, Banovi M, Bere\u010di\u0107 I, Bani\u0107 T, Babi\u0107Leko M, Ulamec M, Junakovi A, Kopi\u0107 J, Serti\u0107 J, Bari\u0161i\u0107 N, \u0160imi\u0107 G (2023) Molecular biomarkers for the diagnosis, prognosis, and pharmacodynamics of spinal muscular atrophy. Journal of clinical medicine. J Clin Med 12:5060. https:\/\/doi.org\/10.3390\/jcm12155060","journal-title":"J Clin Med"},{"key":"5426_CR18","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.3390\/biomedicines11051254","volume":"11","author":"M Meneri","year":"2023","unstructured":"Meneri M, Abati E, Gagliardi D, Faravelli I, Parente V, Ratti A, Verde F, Ticozzi N, Comi GP, Ottoboni L, Corti S (2023) Identification of novel biomarkers of spinal muscular atrophy and therapeutic response by Proteomic and Metabolomic Profiling of Human Biological Fluid samples. Biomedicines 11:1254. https:\/\/doi.org\/10.3390\/biomedicines11051254","journal-title":"Biomedicines"},{"key":"5426_CR19","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.3390\/ijms22052761","volume":"22","author":"CH Chang","year":"2021","unstructured":"Chang CH, Lin CH, Lane HY (2021) Machine learning and novel biomarkers for the diagnosis of Alzheimer\u2019s Disease. Int J Mol Sci 22:2761. https:\/\/doi.org\/10.3390\/ijms22052761","journal-title":"Int J Mol Sci"},{"key":"5426_CR20","doi-asserted-by":"publisher","first-page":"914830","DOI":"10.3389\/fnmol.2022.914830","volume":"15","author":"L M\u00e9gret","year":"2022","unstructured":"M\u00e9gret L, Mendoza C, Arrieta Lobo M, Brouillet E, Nguyen TT, Bouaziz O, Chambaz A, N\u00e9ri C (2022) Precision machine learning to understand micro-RNA regulation in neurodegenerative diseases. Front Mol Neurosci 15:914830. https:\/\/doi.org\/10.3389\/fnmol.2022.914830","journal-title":"Front Mol Neurosci"},{"key":"5426_CR21","doi-asserted-by":"publisher","first-page":"111717","DOI":"10.1016\/j.celrep.2022.111717","volume":"41","author":"J Xu","year":"2022","unstructured":"Xu J, Mao C, Hou Y, Luo Y, Binder JL, Zhou Y, Bekris LM, Shin J, Hu M, Wang F, Eng C, Oprea TI, Flanagan ME, Pieper AA, Cummings J, Leverenz JB, Cheng F (2022) Interpretable deep learning translation of GWAS and multi-omics findings to identify pathobiology and drug repurposing in Alzheimer\u2019s disease. Cell Rep 41:111717. https:\/\/doi.org\/10.1016\/j.celrep.2022.111717","journal-title":"Cell Rep"},{"key":"5426_CR22","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1093\/brain\/awad075","volume":"146","author":"A Catanese","year":"2023","unstructured":"Catanese A, Rajkumar S, Sommer D, Masrori P, Hersmus N, Van Damme P, Witzel S, Ludolph A, Ho R, Boeckers TM, Mulaw M (2023) Multiomics and machine-learning identify novel transcriptional and mutational signatures in amyotrophic lateral sclerosis. Brain 146:3770\u20133782. https:\/\/doi.org\/10.1093\/brain\/awad075","journal-title":"Brain"},{"key":"5426_CR23","doi-asserted-by":"publisher","first-page":"14683","DOI":"10.1038\/s41598-022-14395-4","volume":"12","author":"E Elhaik","year":"2022","unstructured":"Elhaik E (2022) Principal component analyses (PCA)-based findings in population genetic studies are highly biased and must be reevaluated. Sci Rep 12:14683. https:\/\/doi.org\/10.1038\/s41598-022-14395-4","journal-title":"Sci Rep"},{"key":"5426_CR24","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1186\/s12974-020-02025-7","volume":"17","author":"M Naughton","year":"2020","unstructured":"Naughton M, Moffat J, Eleftheriadis G, de la Vega Gallardo N, Young A, Falconer J, Hawkins K, Pearson B, Perbal B, Hogan A, Moynagh P, Loveless S, Robertson NP, Gran B, Kee R, Hughes S, McDonnell G, Howell O, Fitzgerald DC (2020) CCN3 is dynamically regulated by treatment and disease state in multiple sclerosis. J Neuroinflammation 17:349. https:\/\/doi.org\/10.1186\/s12974-020-02025-7","journal-title":"J Neuroinflammation"},{"key":"5426_CR25","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.devcel.2023.06.005","volume":"58","author":"NM O\u2019Brown","year":"2023","unstructured":"O\u2019Brown NM, Patel NB, Hartmann U, Klein AM, Gu C, Megason SG (2023) The secreted neuronal signal Spock1 promotes blood-brain barrier development. Dev Cell 58:1534\u20131547e6. https:\/\/doi.org\/10.1016\/j.devcel.2023.06.005","journal-title":"Dev Cell"},{"key":"5426_CR26","doi-asserted-by":"publisher","first-page":"134462","DOI":"10.1016\/j.neulet.2019.134462","volume":"711","author":"MS Lyon","year":"2019","unstructured":"Lyon MS, Milligan C (2019) Extracellular heat shock proteins in neurodegenerative diseases: new perspectives. Neurosci Lett 711:134462. https:\/\/doi.org\/10.1016\/j.neulet.2019.134462","journal-title":"Neurosci Lett"},{"key":"5426_CR27","doi-asserted-by":"publisher","first-page":"884","DOI":"10.3390\/cells10040884","volume":"10","author":"R Rajendran","year":"2021","unstructured":"Rajendran R, B\u00f6ttiger G, Stadelmann C, Karnati S, Berghoff M (2021) FGF\/FGFR pathways in multiple sclerosis and in its Disease models. Cells 10:884. https:\/\/doi.org\/10.3390\/cells10040884","journal-title":"Cells"},{"key":"5426_CR28","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/s41582-020-0350-6","volume":"16","author":"J Montaner","year":"2020","unstructured":"Montaner J, Ramiro L, Simats A, Tiedt S, Makris K, Jickling GC, Debette S, Sanchez JC, Bustamante A (2020) Multilevel omics for the discovery of biomarkers and therapeutic targets for stroke. Nat Rev Neurol 16:247\u2013264. https:\/\/doi.org\/10.1038\/s41582-020-0350-6","journal-title":"Nat Rev Neurol"},{"key":"5426_CR29","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00018-022-04614-6","volume":"79","author":"Q Aerqin","year":"2022","unstructured":"Aerqin Q, Wang ZT, Wu KM, He XY, Dong Q, Yu JT (2022) Omics-based biomarkers discovery for Alzheimer\u2019s disease. Cell Mol Life Sci 79:585. https:\/\/doi.org\/10.1007\/s00018-022-04614-6","journal-title":"Cell Mol Life Sci"},{"key":"5426_CR30","doi-asserted-by":"publisher","first-page":"9299","DOI":"10.3390\/ijms23169299","volume":"23","author":"R Raghunathan","year":"2022","unstructured":"Raghunathan R, Turajane K, Wong LC (2022) Biomarkers in neurodegenerative diseases: Proteomics spotlight on ALS and Parkinson\u2019s Disease. Int J Mol Sci 23:9299. https:\/\/doi.org\/10.3390\/ijms23169299","journal-title":"Int J Mol Sci"},{"key":"5426_CR31","doi-asserted-by":"publisher","first-page":"792227","DOI":"10.3389\/fneur.2021.792227","volume":"12","author":"A Schumacher-Schuh","year":"2022","unstructured":"Schumacher-Schuh A, Bieger A, Borelli WV, Portley MK, Awad PS, Bandres-Ciga S (2022) Advances in Proteomic and metabolomic profiling of neurodegenerative diseases. Front Neurol 12:792227. https:\/\/doi.org\/10.3389\/fneur.2021.792227","journal-title":"Front Neurol"},{"key":"5426_CR32","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12920-020-00826-6","volume":"13","author":"A Acharjee","year":"2020","unstructured":"Acharjee A, Larkman J, Xu Y, Cardoso VR, Gkoutos G (2020) A random forest based biomarker discovery and power analysis framework for diagnostics research. BMC Med Genomics 13:178. https:\/\/doi.org\/10.1186\/s12920-020-00826-6","journal-title":"BMC Med Genomics"},{"key":"5426_CR33","doi-asserted-by":"publisher","unstructured":"Bettencourt C, Skene N, Bandres-Ciga S, Anderson E, Winchester LM, Foote IF, Schwartzentruber J, Botia JA, Nalls M, Singleton A, Schilder BM, Humphrey J, Marzi SJ, Toomey CE, Kleifat AA, Harshfield EL, Garfield V, Sandor C, Keat S, Tamburin S, Frigerio CS, Lourida I; Deep Dementia Phenotyping (DEMON) Network;, Ranson JM, Llewellyn DJ (2023) Artificial intelligence for dementia genetics and omics. Alzheimers Dement 19:5905\u20135921. https:\/\/doi.org\/10.1002\/alz.13427","DOI":"10.1002\/alz.13427"},{"key":"5426_CR34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3390\/life11010051","volume":"11","author":"I Kalafatakis","year":"2021","unstructured":"Kalafatakis I, Savvaki M, Velona T, Karagogeos D (2021) Implication of contactins in demyelinating pathologies. Life (Basel) 11:51. https:\/\/doi.org\/10.3390\/life11010051","journal-title":"Life (Basel)"},{"key":"5426_CR35","doi-asserted-by":"publisher","first-page":"8354","DOI":"10.1523\/JNEUROSCI.20-22-08354.2000","volume":"20","author":"JC Rios","year":"2000","unstructured":"Rios JC, Melendez-Vasquez CV, Einheber S, Lustig M, Grumet M, Hemperly J, Peles E, Salzer JL (2000) Contactin-associated protein (Caspr) and contactin form a complex that is targeted to the paranodal junctions during myelination. J Neurosci 20:8354\u20138364. https:\/\/doi.org\/10.1523\/JNEUROSCI.20-22-08354.2000","journal-title":"J Neurosci"},{"key":"5426_CR36","doi-asserted-by":"publisher","first-page":"eabb6871","DOI":"10.1126\/scitranslmed.abb6871","volume":"13","author":"L Kong","year":"2021","unstructured":"Kong L, Valdivia DO, Simon CM, Hassinan CW, Delestr\u00e9e N, Ramos DM, Park JH, Pilato CM, Xu X, Crowder M, Grzyb CC, King ZA, Petrillo M, Swoboda KJ, Davis C, Lutz CM, Stephan AH, Zhao X, Weetall M, Naryshkin NA, Crawford TO, Mentis GZ, Sumner CJ (2021) Impaired prenatal motor axon development necessitates early therapeutic intervention in severe SMA. Sci Transl Med 13:eabb6871. https:\/\/doi.org\/10.1126\/scitranslmed.abb6871","journal-title":"Sci Transl Med"},{"key":"5426_CR37","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.1038\/s41467-019-12789-z","volume":"10","author":"M Djannatian","year":"2019","unstructured":"Djannatian M, Timmler S, Arends M, Luckner M, Weil MT, Alexopoulos I, Snaidero N, Schmid B, Misgeld T, M\u00f6bius W, Schifferer M, Peles E, Simons M (2019) Two adhesive systems cooperatively regulate axon ensheathment and myelin growth in the CNS. Nat Commun 10:4794. https:\/\/doi.org\/10.1038\/s41467-019-12789-z","journal-title":"Nat Commun"},{"key":"5426_CR38","doi-asserted-by":"publisher","first-page":"e0157426","DOI":"10.1371\/journal.pone.0157426","volume":"11","author":"CW Yang","year":"2016","unstructured":"Yang CW, Chen CL, Chou WC, Lin HC, Jong YJ, Tsai LK, Chuang CY (2016) An Integrative Transcriptomic Analysis for identifying Novel Target genes corresponding to Severity Spectrum in spinal muscular atrophy. PLoS ONE 11:e0157426. https:\/\/doi.org\/10.1371\/journal.pone.0157426","journal-title":"PLoS ONE"},{"key":"5426_CR39","doi-asserted-by":"publisher","first-page":"147347","DOI":"10.1016\/j.gene.2023.147347","volume":"867","author":"N Kamal","year":"2023","unstructured":"Kamal N, Jafari Khamirani H, Dara M, Dianatpour M (2023) NRXN3 mutations cause developmental delay, movement disorder, and behavioral problems: CRISPR edited cells based WES results. Gene 2023 867:147347. https:\/\/doi.org\/10.1016\/j.gene.2023.147347","journal-title":"Gene 2023"},{"key":"5426_CR40","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1038\/s41467-023-40419-2","volume":"14","author":"BA Lloyd","year":"2023","unstructured":"Lloyd BA, Han Y, Roth R, Zhang B, Aoto J (2023) Neurexin-3 subsynaptic densities are spatially distinct from Neurexin-1 and essential for excitatory synapse nanoscale organization in the hippocampus. Nat Commun 14:4706. https:\/\/doi.org\/10.1038\/s41467-023-40419-2","journal-title":"Nat Commun"},{"key":"5426_CR41","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1038\/s41467-023-36872-8","volume":"14","author":"JH Trotter","year":"2023","unstructured":"Trotter JH, Wang CY, Zhou P, Nakahara G, S\u00fcdhof TC (2023) A combinatorial code of neurexin-3 alternative splicing controls inhibitory synapses via a trans-synaptic dystroglycan signaling loop. Nat Commun 14:1771. https:\/\/doi.org\/10.1038\/s41467-023-36872-8","journal-title":"Nat Commun"},{"key":"5426_CR42","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/hmg\/ddt567","volume":"23","author":"K See","year":"2014","unstructured":"See K, Yadav P, Giegerich M, Cheong PS, Graf M, Vyas H, Lee SG, Mathavan S, Fischer U, Sendtner M, Winkler C (2014) SMN deficiency alters Nrxn2 expression and splicing in zebrafish and mouse models of spinal muscular atrophy. Hum Mol Genet 23:1754\u20131770. https:\/\/doi.org\/10.1093\/hmg\/ddt567","journal-title":"Hum Mol Genet"},{"key":"5426_CR43","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/brain\/awy330","volume":"142","author":"F Rizzo","year":"2019","unstructured":"Rizzo F, Nizzardo M, Vashisht S, Molteni E, Melzi V, Taiana M, Salani S, Santonicola P, Di Schiavi E, Bucchia M, Bordoni A, Faravelli I, Bresolin N, Comi GP, Pozzoli U, Corti S (2019) Key role of SMN\/SYNCRIP and RNA-Motif 7 in spinal muscular atrophy: RNA-Seq and motif analysis of human motor neurons. Brain 142:276\u2013294. https:\/\/doi.org\/10.1093\/brain\/awy330","journal-title":"Brain"},{"key":"5426_CR44","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3233\/JND-221510","volume":"9","author":"A Blaschek","year":"2022","unstructured":"Blaschek A, K\u00f6lbel H, Schwartz O, K\u00f6hler C, Gl\u00e4ser D, Eggermann K, Hannibal I, Schara-Schmidt U, M\u00fcller-Felber W, Vill K (2022) Newborn screening for SMA - can a wait-and-see strategy be responsibly justified in patients with four SMN2 copies? J Neuromuscul Dis 9:597\u2013605. https:\/\/doi.org\/10.3233\/JND-221510","journal-title":"J Neuromuscul Dis"},{"key":"5426_CR45","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1002\/acn3.51449","volume":"8","author":"E Nitz","year":"2021","unstructured":"Nitz E, Smitka M, Schallner J, Akg\u00fcn K, Ziemssen T, von der Hagen M, T\u00fcngler V (2021) Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children. Ann Clin Transl Neurol 8:2013\u20132024. https:\/\/doi.org\/10.1002\/acn3.51449","journal-title":"Ann Clin Transl Neurol"},{"key":"5426_CR46","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1007\/s00415-019-09389-8","volume":"266","author":"B Olsson","year":"2019","unstructured":"Olsson B, Alberg L, Cullen NC, Michael E, Wahlgren L, Kroksmark AK, Rostasy K, Blennow K, Zetterberg H, Tulinius M (2019) NFL is a marker of treatment response in children with SMA treated with nusinersen. J Neurol 266:2129\u20132136. https:\/\/","journal-title":"J Neurol"},{"key":"5426_CR47","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1136\/jnnp-2020-324254","volume":"92","author":"D Kariyawasam","year":"2020","unstructured":"Kariyawasam D, D\u2019Silva A, Howells J, Herbert K, Geelan-Small P, Lin CS, Farrar MA (2020) Motor unit changes in children with symptomatic spinal muscular atrophy treated with nusinersen. J Neurol Neurosurg Psychiatry 92:78\u201385. https:\/\/doi.org\/10.1136\/jnnp-2020-324254","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5426_CR48","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1113\/JP282249","volume":"600","author":"DST Kariyawasam","year":"2022","unstructured":"Kariyawasam DST, D\u2019Silva AM, Herbert K, Howells J, Carey K, Kandula T, Farrar MA, Lin CS (2022) Axonal excitability changes in children with spinal muscular atrophy treated with nusinersen. J Physiol 600:95\u2013109. https:\/\/doi.org\/10.1113\/JP282249","journal-title":"J Physiol"},{"key":"5426_CR49","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1111\/jcmm.14939","volume":"24","author":"I Faravelli","year":"2020","unstructured":"Faravelli I, Meneri M, Saccomanno D, Velardo D, Abati E, Gagliardi D, Parente V, Petrozzi L, Ronchi D, Stocchetti N, Calderini E, D\u2019Angelo G, Chidini G, Prandi E, Ricci G, Siciliano G, Bresolin N, Comi GP, Corti S, Magri F, Govoni A (2020) Nusinersen treatment and cerebrospinal fluid neurofilaments: an explorative study on spinal muscular atrophy type 3 patients. J Cell Mol Med 24:3034\u20133039. https:\/\/doi.org\/10.1111\/jcmm.14939","journal-title":"J Cell Mol Med"},{"key":"5426_CR50","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/acn3.779","volume":"6","author":"BT Darras","year":"2019","unstructured":"Darras BT, Crawford TO, Finkel RS, Mercuri E, De Vivo DC, Oskoui M, Tizzano EF, Ryan MM, Muntoni F, Zhao G, Staropoli J, McCampbell A, Petrillo M, Stebbins C, Fradette S, Farwell W, Sumner CJ (2019) Neurofilament as a potential biomarker for spinal muscular atrophy. Ann Clin Transl Neurol 6:932\u2013944. https:\/\/doi.org\/10.1002\/acn3.779","journal-title":"Ann Clin Transl Neurol"},{"key":"5426_CR51","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s40261-021-01071-0","volume":"41","author":"G Milella","year":"2021","unstructured":"Milella G, Introna A, D\u2019Errico E, Fraddosio A, Scaglione G, Morea A, Ucci M, Ruggieri M, Mastrapasqua M, Megna M, Puntillo F, Simone IL (2021) Cerebrospinal fluid and clinical profiles in adult type 2\u20133 spinal muscular atrophy patients treated with Nusinersen: an 18-Month single-centre experience. Clin Drug Investig 41:775\u2013784. https:\/\/doi.org\/10.1007\/s40261-021-01071-0","journal-title":"Clin Drug Investig"},{"key":"5426_CR52","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s00415-019-09547-y","volume":"267","author":"CD Wurster","year":"2020","unstructured":"Wurster CD, Steinacker P, G\u00fcnther R, Koch JC, Lingor P, Uzelac Z, Witzel S, Wollinsky K, Winter B, Osmanovic A, Schreiber-Katz O, Al Shweiki R, Ludolph AC, Petri S, Hermann A, Otto M, MND-Net (2020) Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen. J Neurol 267:36\u201344. https:\/\/doi.org\/10.1007\/s00415-019-09547-y","journal-title":"J Neurol"},{"key":"5426_CR53","doi-asserted-by":"publisher","first-page":"672891","DOI":"10.3389\/fnsyn.2021.672891","volume":"13","author":"D Carulli","year":"2021","unstructured":"Carulli D, de Winter F, Verhaagen J (2021) Semaphorins in adult nervous system plasticity and disease. Front Synaptic Neurosci 13:672891. https:\/\/doi.org\/10.3389\/fnsyn.2021.672891","journal-title":"Front Synaptic Neurosci"},{"key":"5426_CR54","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1212\/01.wnl.0000086813.59722.72","volume":"61","author":"MC \u00d8rngreen","year":"2003","unstructured":"\u00d8rngreen MC, Zacho M, Hebert A, Laub M, Vissing J (2003) Patients with severe muscle wasting are prone to develop hypoglycemia during fasting. Neurology 61:997\u20131000. https:\/\/doi.org\/10.1212\/01.wnl.0000086813.59722.72","journal-title":"Neurology"},{"key":"5426_CR55","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1136\/archdischild-2019-318120","volume":"105","author":"B Berti","year":"2020","unstructured":"Berti B, Onesimo R, Leone D, Palermo C, Giorgio V, Buonsenso D, Pane M, Mercuri E (2020) Hypoglycaemia in patients with type 1 SMA: an underdiagnosed problem? Arch Dis Child 105:707. https:\/\/doi.org\/10.1136\/archdischild-2019-318120","journal-title":"Arch Dis Child"},{"key":"5426_CR56","doi-asserted-by":"publisher","first-page":"5913","DOI":"10.3390\/ijms22115913","volume":"22","author":"MO Deguise","year":"2021","unstructured":"Deguise MO, Chehade L, Kothary R (2021) Metabolic dysfunction in spinal muscular atrophy. Int J Mol Sci 22:5913. https:\/\/doi.org\/10.3390\/ijms22115913","journal-title":"Int J Mol Sci"},{"key":"5426_CR57","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1111\/apa.16074","volume":"110","author":"MC \u00d8rngreen","year":"2021","unstructured":"\u00d8rngreen MC, Andersen AG, Eisum AS, Hald EJ, Raaschou-Pedersen DE, L\u00f8kken N, H\u00f8i-Hansen CE, Vissing J, Born AP, van Hall G (2021) Prolonged fasting-induced hyperketosis, hypoglycaemia and impaired fat oxidation in child and adult patients with spinal muscular atrophy type II. Acta Paediatr 110:3367\u20133375. https:\/\/doi.org\/10.1111\/apa.16074","journal-title":"Acta Paediatr"},{"key":"5426_CR58","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/978-0-387-78952-1_6","volume":"632","author":"U Amara","year":"2008","unstructured":"Amara U, Rittirsch D, Flierl M, Bruckner U, Klos A, Gebhard F, Lambris JD, Huber-Lang M (2008) Interaction between the coagulation and complement system. Adv Exp Med Biol 632:71\u201379. https:\/\/doi.org\/10.1007\/978-0-387-78952-1_6","journal-title":"Adv Exp Med Biol"},{"key":"5426_CR59","doi-asserted-by":"publisher","first-page":"5628","DOI":"10.4049\/jimmunol.0903678","volume":"185","author":"U Amara","year":"2010","unstructured":"Amara U, Flierl MA, Rittirsch D, Klos A, Chen H, Acker B, Br\u00fcckner UB, Nilsson B, Gebhard F, Lambris JD, Huber-Lang M (2010) Molecular intercommunication between the complement and coagulation systems. J Immunol 185:5628\u20135636. https:\/\/doi.org\/10.4049\/jimmunol.0903678","journal-title":"J Immunol"},{"key":"5426_CR60","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/s0968-0004(01)02007-2","volume":"27","author":"MM Krem","year":"2002","unstructured":"Krem MM, Di Cera E (2002) Evolution of enzyme cascades from embryonic development to blood coagulation. Trends Biochem Sci 27:67\u201374. https:\/\/doi.org\/10.1016\/s0968-0004(01)02007-2","journal-title":"Trends Biochem Sci"},{"key":"5426_CR61","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/nri2402","volume":"8","author":"D Rittirsch","year":"2008","unstructured":"Rittirsch D, Flierl MA, Ward PA (2008) Harmful molecular mechanisms in sepsis. Nat Rev Immunol 8:776\u2013787. https:\/\/doi.org\/10.1038\/nri2402","journal-title":"Nat Rev Immunol"},{"key":"5426_CR62","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3389\/fnins.2020.00023","volume":"14","author":"J Magdalon","year":"2020","unstructured":"Magdalon J, Mansur F, Teles E, Silva AL, de Goes VA, Reiner O, Serti\u00e9 AL (2020) Complement system in Brain Architecture and Neurodevelopmental disorders. Front Neurosci 14:23. https:\/\/doi.org\/10.3389\/fnins.2020.00023","journal-title":"Front Neurosci"},{"key":"5426_CR63","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.cell.2007.10.036","volume":"131","author":"B Stevens","year":"2007","unstructured":"Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N, Micheva KD, Mehalow AK, Huberman AD, Stafford B, Sher A, Litke AM, Lambris JD, Smith SJ, John SW, Barres BA (2007) The classical complement cascade mediates CNS synapse elimination. Cell 131:1164\u20131178. https:\/\/doi.org\/10.1016\/j.cell.2007.10.036","journal-title":"Cell"},{"key":"5426_CR64","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1016\/j.celrep.2019.11.013","volume":"29","author":"A Vukojicic","year":"2019","unstructured":"Vukojicic A, Delestr\u00e9e N, Fletcher EV, Pagiazitis JG, Sankaranarayanan S, Yednock TA, Barres BA, Mentis GZ (2019) The classical complement pathway mediates Microglia-Dependent remodeling of spinal motor circuits during development and in SMA. Cell Rep 29:3087\u20133100e7. https:\/\/doi.org\/10.1016\/j.celrep.2019.11.013","journal-title":"Cell Rep"},{"key":"5426_CR65","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3390\/ph13110341","volume":"13","author":"M Gavriilaki","year":"2020","unstructured":"Gavriilaki M, Kimiskidis VK, Gavriilaki E (2020) Precision Medicine in Neurology: the inspirational paradigm of complement therapeutics. Pharmaceuticals (Basel) 13:341. https:\/\/doi.org\/10.3390\/ph13110341","journal-title":"Pharmaceuticals (Basel)"},{"key":"5426_CR66","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/acn3.423","volume":"4","author":"MO Deguise","year":"2017","unstructured":"Deguise MO, Kothary R (2017) New insights into SMA pathogenesis: immune dysfunction and neuroinflammation. Ann Clin Transl Neurol 4:522\u2013530. https:\/\/doi.org\/10.1002\/acn3.423","journal-title":"Ann Clin Transl Neurol"},{"key":"5426_CR67","doi-asserted-by":"publisher","first-page":"4061","DOI":"10.1093\/hmg\/ddy300","volume":"27","author":"B Wan","year":"2018","unstructured":"Wan B, Feng P, Guan Z, Sheng L, Liu Z, Hua Y (2018) A severe mouse model of spinal muscular atrophy develops early systemic inflammation. Hum Mol Genet 27:4061\u20134076. https:\/\/doi.org\/10.1093\/hmg\/ddy300","journal-title":"Hum Mol Genet"},{"key":"5426_CR68","doi-asserted-by":"publisher","first-page":"982760","DOI":"10.3389\/fncel.2022.982760","volume":"16","author":"S Bonanno","year":"2022","unstructured":"Bonanno S, Cavalcante P, Salvi E, Giagnorio E, Malacarne C, Cattaneo M, Andreetta F, Venerando A, Pensato V, Gellera C, Zanin R, Arnoldi MT, Dosi C, Mantegazza R, Masson R, Maggi L, Marcuzzo S (2022) Identification of a cytokine profile in serum and cerebrospinal fluid of pediatric and adult spinal muscular atrophy patients and its modulation upon nusinersen treatment. Front Cell Neurosci 16:982760. https:\/\/doi.org\/10.3389\/fncel.2022.982760","journal-title":"Front Cell Neurosci"},{"key":"5426_CR69","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s43856-023-00256-2","volume":"3","author":"T Nuzzo","year":"2023","unstructured":"Nuzzo T, Russo R, Errico F, D\u2019Amico A, Tewelde AG, Valletta M, Hassan A, Tosi M, Panicucci C, Bruno C, Bertini E, Chambery A, Pellizzoni L, Usiello A (2023) Nusinersen mitigates neuroinflammation in severe spinal muscular atrophy patients. Commun Med (Lond) 3:28. https:\/\/doi.org\/10.1038\/s43856-023-00256-2","journal-title":"Commun Med (Lond)"},{"key":"5426_CR70","doi-asserted-by":"publisher","first-page":"e696","DOI":"10.1212\/WNL.0000000000006050","volume":"91","author":"M Pane","year":"2018","unstructured":"Pane M, Palermo C, Messina S, Sansone VA, Bruno C, Catteruccia M, Sframeli M, Albamonte E, Pedemonte M, D\u2019Amico A, Brigati G, de Sanctis R, Coratti G, Lucibello S, Bertini E, Vita G, Danilo Tiziano F, Mercuri E, Italian EAP, Working Group (2018) An observational study of functional abilities in infants, children, and adults with type 1 SMA. Neurol 2018 91:e696\u2013e703. https:\/\/doi.org\/10.1212\/WNL.0000000000006050","journal-title":"Neurol 2018"},{"key":"5426_CR71","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.nmd.2009.11.014","volume":"20","author":"AM Glanzman","year":"2010","unstructured":"Glanzman AM, Mazzone E, Main M, Pelliccioni M, Wood J, Swoboda KJ, Scott C, Pane M, Messina S, Bertini E, Mercuri E, Finkel RS (2010) The children\u2019s hospital of Philadelphia Infant Test of Neuromuscular disorders (CHOP INTEND): test development and reliability. Neuromuscul Disord 20:155\u2013161. https:\/\/doi.org\/10.1016\/j.nmd.2009.11.014","journal-title":"Neuromuscul Disord"},{"key":"5426_CR72","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.nmd.2007.05.009","volume":"17","author":"JM O\u2019Hagen","year":"2007","unstructured":"O\u2019Hagen JM, Glanzman AM, McDermott MP, Ryan PA, Flickinger J, Quigley J, Riley S, Sanborn E, Irvine C, Martens WB, Annis C, Tawil R, Oskoui M, Darras BT, Finkel RS, De Vivo DC (2007) An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients. Neuromuscul Disord 17:693\u2013697. https:\/\/doi.org\/10.1016\/j.nmd.2007.05.009","journal-title":"Neuromuscul Disord"},{"key":"5426_CR73","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, Chiriboga CA, Saito K, Servais L, Tizzano E, Topaloglu H, Tulinius M, Montes J, Glanzman AM, Bishop K, Zhong ZJ, Gheuens S, Bennett CF, Schneider E, Farwell W, De Vivo DC, ENDEAR Study Group (2017) Nusinersen versus Sham Control in infantile-onset spinal muscular atrophy. N Engl J Med 377:1723\u20131732. https:\/\/doi.org\/10.1056\/NEJMoa1702752","journal-title":"N Engl J Med"},{"key":"5426_CR74","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1186\/s13023-022-02547-8","volume":"17","author":"A Pechmann","year":"2022","unstructured":"Pechmann A, Behrens M, D\u00f6rnbrack K, Tassoni A, Wenzel F, Stein S, Vogt S, Z\u00f6ller D, Bernert G, Hagenacker T, Schara-Schmidt U, Walter MC, Bertsche A, Vill K, Baumann M, Baumgartner M, Cordts I, Eisenk\u00f6lbl A, Flotats-Bastardas M, Friese J, G\u00fcnther R, Hahn A, Horber V, Husain RA, Illsinger S, Jahnel J, Johannsen J, K\u00f6hler C, K\u00f6lbel H, M\u00fcller M, von Moers A, Schwerin-Nagel A, Reihle C, Schlachter K, Schreiber G, Schwartz O, Smitka M, Steiner E, Trollmann R, Weiler M, Wei\u00df C, Wiegand G, Wilichowski E, Ziegler A, Lochm\u00fcller H, Kirschner J, SMArtCARE study group (2022) Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study. Orphanet J Rare Dis 17:384. https:\/\/doi.org\/10.1186\/s13023-022-02547-8","journal-title":"Orphanet J Rare Dis"},{"key":"5426_CR75","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1074\/mcp.TIR118.001270","volume":"18","author":"TS Batth","year":"2019","unstructured":"Batth TS, Tollenaere MX, R\u00fcther P, Gonzalez-Franquesa A, Prabhakar BS, Bekker-Jensen S, Deshmukh AS, Olsen JV (2019) Protein aggregation capture on Microparticles enables Multipurpose Proteomics Sample Preparation. Mol Cell Proteom 18:1027\u20131035. https:\/\/doi.org\/10.1074\/mcp.TIR118.001270","journal-title":"Mol Cell Proteom"},{"key":"5426_CR76","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/nmeth.2834","volume":"11","author":"NA Kulak","year":"2014","unstructured":"Kulak NA, Pichler G, Paron I, Nagaraj N, Mann M (2014) Minimal, encapsulated proteomic-sample processing applied to copy-number estimation in eukaryotic cells. Nat Methods 11:319\u2013324. https:\/\/doi.org\/10.1038\/nmeth.2834","journal-title":"Nat Methods"},{"key":"5426_CR77","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/nbt.1511","volume":"26","author":"J Cox","year":"2008","unstructured":"Cox J, Mann M (2008) MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 26:1367\u20131372. https:\/\/doi.org\/10.1038\/nbt.1511","journal-title":"Nat Biotechnol"},{"key":"5426_CR78","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1021\/acs.jproteome.7b00595","volume":"17","author":"FM Alakwaa","year":"2018","unstructured":"Alakwaa FM, Chaudhary K, Garmire LX (2018) Deep learning accurately predicts estrogen receptor status in breast Cancer Metabolomics Data. J Proteome Res 17:337\u2013347. https:\/\/doi.org\/10.1021\/acs.jproteome.7b00595","journal-title":"J Proteome Res"},{"key":"5426_CR79","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/uog.20168","volume":"54","author":"RO Bahado-Singh","year":"2019","unstructured":"Bahado-Singh RO, Sonek J, McKenna D, Cool D, Aydas B, Turkoglu O, Bjorndahl T, Mandal R, Wishart D, Friedman P, Graham SF, Yilmaz A (2019) Artificial intelligence and amniotic fluid multiomics: prediction of perinatal outcome in asymptomatic women with short cervix. Ultrasound Obstet Gynecol 54:110\u2013118. https:\/\/doi.org\/10.1002\/uog.20168","journal-title":"Ultrasound Obstet Gynecol"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-024-05426-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-024-05426-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-024-05426-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T17:08:25Z","timestamp":1725988105000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-024-05426-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,10]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["5426"],"URL":"https:\/\/doi.org\/10.1007\/s00018-024-05426-6","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,10]]},"assertion":[{"value":"25 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and ICH GCP guidelines. All subjects and guardians provided written informed consent for the analysis of biological samples, following the approval of local ethics committees (Prot. SMALiQ_2022, 503\/2022 - id 12319).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Authors gave consent for the publication of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"393"}}